CERT Stock Chart & Stats
$219.68
$0.00(0.00%)
―
--
Day’s Range― - ―
52-Week Range$219.68 - $219.68
Previous CloseN/A
VolumeN/A
Average Volume (3M)0.00
Market Cap
$20.43B
Enterprise Value$1.05K
Total Cash (Recent Filing)$149.48M
Total Debt (Recent Filing)$300.26M
Price to Earnings (P/E)―
Beta0.33
Next Earnings
Aug 04, 2026EPS Estimate
1.56Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.09
Shares Outstanding155,564,600
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio10.16
Price to Book (P/B)1.33
Price to Sales (P/S)3.37
P/FCF Ratio14.94
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Very Conservative Balance Sheet / Low LeverageCertara's extremely low reported leverage and roughly $1.0B equity base provide durable financial flexibility. This supports continued R&D, strategic M&A or buybacks, and resilience through cyclical variability, reducing refinancing risk and enabling multi‑quarter execution of strategic plans.
High Recurring Software Revenue And RetentionA >100% net retention rate and a majority of ratable subscription software revenue underpin predictable, scalable revenue and stronger margin sustainability. Recurring licensing helps smooth cash flow, improves visibility into future periods, and strengthens customer stickiness over multiple quarters.
Product, AI Momentum And Strategic PartnershipsInvestments in AI capabilities, an AI leadership hire, and partnerships with NVIDIA and Altasciences support durable product differentiation and platform scalability. These moves can accelerate compute-heavy biosimulation, deepen ecosystem ties, and increase barriers to entry versus pure services competitors.
Bears Say
Ongoing GAAP Losses And Profitability VolatilityRepeated GAAP losses and swings in quarterly profitability signal the company has yet to consistently convert revenue and strong gross margins into net earnings. Persistent net losses constrain retained earnings, reduce ROE, and limit the margin of safety for sustained investment without relying on non‑operational funding.
Services Revenue And Bookings WeaknessDeclining services revenue and markedly weaker services bookings reflect structural go‑to‑market or demand challenges in project work. Because services historically provide customer touchpoints for upsell and cross‑sell, sustained weakness can limit organic growth, reduce backlog conversion, and pressure overall revenue diversification.
Sharp Decline In Free Cash Flow MomentumA ~57.6% TTM drop in free cash flow, despite positive absolute cash generation, indicates weakening cash momentum. If sustained, this reduces internal funding for product development, strategic investments, or buybacks and heightens dependence on operational improvement to restore durable high‑quality cash generation.
CERT FAQ
What was Certara, Inc.’s price range in the past 12 months?
Certara, Inc. lowest stock price was $219.68 and its highest was $219.68 in the past 12 months.
What is Certara, Inc.’s market cap?
Certara, Inc.’s market cap is $20.43B.
When is Certara, Inc.’s upcoming earnings report date?
Certara, Inc.’s upcoming earnings report date is Aug 04, 2026 which is in 9 days.
How were Certara, Inc.’s earnings last quarter?
Certara, Inc. released its earnings results on May 11, 2026. The company reported $1.576 earnings per share for the quarter, missing the consensus estimate of $1.856 by -$0.28.
Is Certara, Inc. overvalued?
According to Wall Street analysts Certara, Inc.’s price is currently Undervalued.
Does Certara, Inc. pay dividends?
Certara, Inc. does not currently pay dividends.
What is Certara, Inc.’s EPS estimate?
Certara, Inc.’s EPS estimate is 1.56.
How many shares outstanding does Certara, Inc. have?
Certara, Inc. has 155,564,600 shares outstanding.
What happened to Certara, Inc.’s price movement after its last earnings report?
Certara, Inc. reported an EPS of $1.576 in its last earnings report, missing expectations of $1.856. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Certara, Inc.?
Currently, no hedge funds are holding shares in MX:CERT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Certara Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-34.16%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-3.88%
Trailing 12-Months
Company Description
Certara, Inc.
Certara, Inc. provides advanced software solutions and technology-driven services, specializing in biosimulation throughout the entire drug development lifecycle. From initial drug discovery and preclinical research to clinical trials, regulatory submissions, and market entry, the company's core mission is to accelerate the delivery of new medicines to patients by transforming these processes with its innovative biosimulation software and expertise. Its extensive portfolio of technology-enabled services includes mechanistic and empirical biosimulation, strategic guidance for drug development and regulatory affairs, clinical pharmacology, model-based meta-analysis, specialized regulatory writing and medical communications, regulatory operations support, and market access consultation. Furthermore, Certara offers a robust suite of software platforms covering mechanistic and empirical PK/PD biosimulation, data standardization and compliance, scientific informatics, clinical outcomes databases for biosimulation, authoring and management of regulatory submissions, and market access communication. The company's clientele primarily comprises biopharmaceutical firms, academic institutions, and governmental organizations. Established in 2008 and headquartered in Princeton, New Jersey, Certara maintains a significant global presence, with operations spanning numerous countries including the United States, Canada, Spain, Luxembourg, Portugal, the United Kingdom, Germany, France, the Netherlands, Denmark, Switzerland, Italy, Poland, Japan, the Philippines, India, Australia, and China.